Clinical efficacy of Reduning injection in the treatment of novel coronavirus pneumonia
-
摘要: 目的 探讨热毒宁注射液治疗新型冠状病毒肺炎的临床疗效。方法 本研究有效纳入新型冠状病毒肺炎患者77例，依据随机数字表法分为两组：治疗组36例，对照组41例。对照组给予西药常规治疗，治疗组在对照组基础上给予热毒宁注射液，治疗观察7 d；分别观察两组的体温、炎症指标、临床疗效。结果 治疗组患者从第3天开始平均体温达到正常范围内，且体温下降较对照组多，在第4天更为显著，两组比较差异有统计学意义(P=0.012)；治疗组患者入院时IL-6水平显著高于对照组，差异有统计学意义(P=0.002)，到第7天降到相同水平，其中从第3天开始降低更为显著。同样从第3天起，治疗组的外周血中性粒细胞数下降、淋巴细胞数升高、NLR下降明显，且NLR下降幅度明显优于对照组，差异有统计学意义(P=0.049)；治疗组患者在第3天CURB-65评分明显低于对照组，两组比较差异有统计学意义(P=0.046)；治疗组CURB-65评分≥3分的患者比例较对照组更少，且病情加重患者例数较对照组明显减少，差异有统计学意义(P=0.04)；治疗组呼吸衰竭(P=0.05)以及转入ICU(P=0.04)的患者例数比例也较对照组明显减少；治疗组的住院天数(P=0.014)、住院费用(P=0.013)以及核酸转阴时间(P=0.024)均明显低于对照组，均差异有统计学意义。结论 热毒宁注射液联合西药常规治疗可提高新型冠状病毒肺炎的临床疗效，在降低体温、缩短发热时间及控制炎症反应、恢复患者免疫水平方面具有优势。Abstract: Objective To investigate the clinical efficacy of Reduning injection in the treatment of novel coronavirus pneumonia.Methods Seventy-seven subjects of corona virus disease 2019(COVID-19)were effectively included in the study, and were divided into groups according to a random number table method. The treatment group consisted of 36 patients, and the control group consisted of 41 patients. The control group received conventional treatment with Western medicine, while the treatment group received injections of Reduning on top of the control group's treatment. The treatment was observed for 7 days. The body temperature, inflammatory indicators, and clinical efficacy of the two groups were observed.Results The average body temperature of the patients who used Reduning injection from the third day reached the normal range, and the body temperature dropped more than that of the control group, especially on the fourth day(P=0.012). The level of IL-6 in the treatment group at admission was significantly higher than that in the control group(P=0.002), and decreased to the same level on the seventh day, with the decrease being more significant since the third day. Similarly, after the third day, the number of neutrophils and lymphocytes in the peripheral blood of the treatment group decreased significantly, while the number of lymphocytes and NLR decreased significantly, and the decline in NLR was significantly obvious than that of the control group (P=0.049). The treatment group had significantly lower CURB-65 score on the third day than the control group (P=0.046), and the proportion of patients with CURB-65 score≥3 was less than that in the control group, and the number of patients with exacerbation was significantly reduced compared with the control group (P=0.04), among which the number and proportion of patients with respiratory failure (P=0.05) and admission to the ICU (P=0.04) were also significantly reduced compared with the control group.The hospitalization days(P=0.014), hospitalization expenses(P=0.013), and nucleic acid negative time(P=0.024) of the treatment group were significantly lower than those of the control group.Conclusion Reduning injection combined with routine Western medicine treatment can improve the clinical efficacy of COVID-19, and has advantages in lowering body temperature, shortening fever time, controlling inflammatory reaction, and restoring the immune level of patients.
-
Key words:
- Reduning injection /
- corona virus disease 2019 /
- temperature /
- inflammatory reaction /
- clinical efficacy
-
-
表 1 CURB-65评分标准
指标 分值/分 意识障碍(C) 1 尿素氮(U)>7 mmol/L 1 呼吸频率(R)≥30次/min 1 血压(B)：SBP < 90 mmHg或DBP≤60 mmHg 1 年龄≥65岁 1 注：1 mmHg=0.133 kPa。 
下载: 导出CSV
表 2 两组患者一般资料特征比较
组别 例数 性别/例 年龄/岁 合并基础疾病/例 男 女 慢性阻塞性肺疾病 高血压 糖尿病 对照组 41 26 15 79.43±13.12 16 23 16 治疗组 36 20 16 83.25±12.22 13 22 10 P < 0.01 0.48 0.19 0.79 0.65 0.29
下载: 导出CSV
表 3 两组患者第1天和第3天CURB-65评分比较
组别 第1天
CURB-65第3天
CURB-65CURB-65
≥3/例对照组 2.82±0.73 2.58±0.92 22 治疗组 2.77±0.76 2.19±0.71 11 P 0.71 0.046 < 0.01
下载: 导出CSV
表 5 两组间临床转归及费用比较
组别 例数 住院天数/d 住院费用/万元 核酸转阴时间/d 对照组 41 19.39±4.84 6.77±1.69 12.65±3.65 治疗组 36 16.1±4.92 5.67±1.67 10.86±3.14 P 0.014 0.013 0.024
下载: 导出CSV
-
[1] Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019(COVID-19): a review[J]. JAMA, 2020, 324(8): 782-793. doi: 10.1001/jama.2020.12839
[2] World Health Organization. Coronavirus disease 2019(COVID-19)pandemic[EB/OL]. [2022-11-28].
https://covid19.who.int/table .[3] 国家卫生健康委办公厅, 国家中医药局综合司. 关于印发新型冠状病毒感染诊疗方案(试行第十版)的通知[S/OL]. [2023-01-05].
https://www.gov.cn/zhengce/zhengceku/2023-01/06/content_5735343.htm .[4] 颜海燕, 王萌, 王辉强, 等. 热毒宁注射液抗流感病毒作用及机制研究[J]. 药学学报, 2023, 58(6): 1596-1602. doi: 10.16438/j.0513-4870.2022-1092
[5] 范震宇, 蔡亮亮, 王亚格, 等. 热毒宁注射液解热作用与化学质控成分相关性研究[J]. 南京中医药大学学报, 2021, 37(1): 126-130. doi: 10.14148/j.issn.1672-0482.2021.0126
[6] Wang Z, Chen W, Li Y, at al. Reduning injection and its effective constituent luteoloside protect against sepsis partly via inhibition of HMGB1/TLR4/NF-κB/MAPKs signaling pathways[J]. J Ethnopharmacol, 2021, 270: 113783. doi: 10.1016/j.jep.2021.113783
[7] Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12.1, BA. 4 and BA. 5[J]. Nature, 2022, 608(7923): 603-608. doi: 10.1038/s41586-022-05053-w
[8] 廖春晓, 王波, 吕筠, 等. 新型冠状病毒Omicron变异株病原学及流行病学研究进展[J]. 中华流行病学杂志, 2022, 43(11): 1691-1698.
[9] 丁彦青, 卞修武. 从SARS尸体解剖发现, 浅析冠状病毒性疾病-19(COVID-19)[J]. 中华病理学杂志, 2020, 49(1): E003-E003.
[10] 留永健, 杨燕丽, 徐燕. 应对新冠肺炎, 我们能从SARS中得到哪些借鉴[J/OL]. (2020-02-22)[2020-02-29]. 中华结核和呼吸杂志, 2020, 43.
[11] 高金梅, 黄映波, 冯珍珍. 单核细胞趋化蛋白-1对67例全身炎症反应综合征患者的诊断价值[J]. 山东大学学报(医学版), 2021, 59(10): 75-79. . https://www.cnki.com.cn/Article/CJFDTOTAL-SDYB202110009.htm
[12] Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy[J]. 2021, 122(7): 474-488.
[13] 王高举, 焦红军. 基于网络药理学和分子对接技术的热毒宁注射液抗SARS、MERS和COVID-19的潜在共性作用机制与活性成分研究[J]. 药物评价研究, 2022, 45(5): 842-852. https://www.cnki.com.cn/Article/CJFDTOTAL-YWPJ202205005.htm
[14] Ma Q, Xie Y, Wang Z, et al. Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2[J]. J Ethnopharmacol, 2021, 279: 114367.
[15] 林昱, 汪华, 李鹏. 热毒宁联合头孢哌酮/舒巴坦钠和替加环素对泛耐药鲍氏不动杆菌肺炎的抑菌效果[J]. 中华医院感染学杂志, 2022, 32(3): 331-335. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY202203003.htm
[16] 陈佳骏, 张海阳, 曲岩, 等. 热毒宁注射液辅助治疗对急性胆囊炎术后患者炎症指标及免疫功能的影响[J]. 临床急诊杂志, 2021, 22(8): 540-543. https://lcjz.whuhzzs.com/article/doi/10.13201/j.issn.1009-5918.2021.08.006
[17] Ma Q, Xie Y, Wang Z, et al. Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2[J]. J Ethnopharmacol, 2021, 279: 114367.
[18] Buonacera A, Stancanelli B, Colaci M, et al. Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases[J]. Int J Mol Sci, 2022, 23(7): 3636. .
[19] Imran MM, Ahmad U, Usman U, et al. eutrophil/lymphocyte ratio-A marker of COVID-19 pneumonia severity[J]. Int J Clin Pract, 2021, 75(4): e1368.
[20] 何祯硕, 高盼, 冀英双, 等. SⅡ与d-NLR在诊断成人社区获得性肺炎中的价值[J]. 国际检验医学杂志, 2023, 44(6): 693-697. https://www.cnki.com.cn/Article/CJFDTOTAL-GWSQ202306011.htm
[21] 李爱新, 梁连春, 李侗曾, 等. 新型冠状病毒肺炎合并心血管疾病患者临床特征与预后影响因素分析[J]. 河北医学, 2020, 26(6): 897-904. https://www.cnki.com.cn/Article/CJFDTOTAL-HCYX202006004.htm
[22] 唐欢. 热毒宁注射液在慢性阻塞性肺疾病急性加重期患者中的疗效观察及对炎性因子和肺功能的影响研究[J]. 山西医药杂志, 2021, 50(2): 257-260. https://www.cnki.com.cn/Article/CJFDTOTAL-SXYY202102038.htm
[23] Kuikel S, Pathak N, Poudel S, et al. Neutrophil-lymphocyte ratio as a predictor of adverse outcome in patients with community-acquired pneumonia: A systematic review[J]. Health Sci Rep, 2022, 5(3): e630.
[24] Yang C, Song C, Liu Y, et al. Re-Du-Ning injection ameliorates LPS-induced lung injury through inhibiting neutrophil extracellular traps formation[J]. Phytomedicine, 2021, 90: 153635.
[25] Li Z, Xie L, Wang H, et al. Clinical Observation of Reduning Combined with Recombinant Human Interferon α-2b in the Treatment of Children with Viral Pneumonia[J]. Evid Based Complement Alternat Med, 2022, 2022: 1739561.
-
图(3)
表(5)
计量
- 文章访问数: 1324
- PDF下载数: 1074
- 施引文献: 0